Robeaute

Robeauté is developing a rice-sized microrobotic platform intended to navigate the brain to diagnose, treat and monitor neurological conditions. The website states the device is in design and has not been cleared by the FDA or CE-marked, so it is not approved for clinical use or commercial sale.

The company's stated audience is neurosurgeons and patients with brain disease; its Medical and Scientific Advisory Board includes neurosurgeons from leading hospitals. The website does not describe a revenue model or named commercial customers.

Robeauté was founded in 2017 in Paris, where its first office was in AP-HP Hôtel-Dieu. The company reports a $28 million Series A in 2025 and a team of 40+, and opened a San Francisco office in 2026 ahead of planned first-in-human studies. Open roles are in Paris, spanning manufacturing, software, clinical affairs, product and HR.

Product: A microrobotic platform for diagnosing, treating and monitoring brain disease, currently in preclinical design.